Bile Acids and Portal Hypertension
- PMID: 29080345
- DOI: 10.5604/01.3001.0010.5500
Bile Acids and Portal Hypertension
Abstract
The recent discovery of bile acid (BA) receptors and a better delineation of the multiple roles of BAs in relevant biological processes have revamped BA research. The vasoactive actions of BAs were recognized more than three decades ago but the underlying mechanisms of the BA-induced vasorelaxation are now being clarified. Recent evidence shows that the BA receptors FXR and TGR5 are expressed in endothelial cells and may have important effects on both systemic and portal circulation. The availability of genetically engineered mice with ablation of BA receptors and the development of BA receptor agonists has allowed to explore the modulation of XR and, in a lesser extent, of TGR5 in the setting of portal hypertension (PHT) with promising results. In this review, we summarize recent data on how BA-dependent pathways influence several processes that impact in PHT and the preclinical data showing that pharmacological modulation of those pathways may hold promise in the treatment of PHT.
Keywords: Bile acids. Hepatic flow. Portal hypertension. Cirrhosis. Farnesoid X receptor. Fibrosis. Cirrhosis. Bacterial translocation. Intestinal permeability. Inflammation..
Similar articles
-
Bile Acids and Portal Hypertension.Ann Hepatol. 2017 Nov;16 Suppl 1:S83-S86. doi: 10.5604/01.3001.0010.5500. Ann Hepatol. 2017. PMID: 31196639
-
Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.Pharmacol Res. 2016 Sep;111:749-756. doi: 10.1016/j.phrs.2016.07.040. Epub 2016 Jul 27. Pharmacol Res. 2016. PMID: 27475883 Review.
-
Hepatic Bile Acid Reuptake in the Rat Depends on Bile Acid Conjugation but Not on Agonistic Properties towards FXR and TGR5.Molecules. 2020 May 20;25(10):2371. doi: 10.3390/molecules25102371. Molecules. 2020. PMID: 32443832 Free PMC article.
-
FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.J Hepatol. 2019 Dec;71(6):1126-1140. doi: 10.1016/j.jhep.2019.06.017. Epub 2019 Jul 8. J Hepatol. 2019. PMID: 31295531
-
Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.Dig Dis. 2016;34(5):580-8. doi: 10.1159/000445268. Epub 2016 Jun 22. Dig Dis. 2016. PMID: 27332721 Review.
Cited by
-
The effects of ursodeoxycholic acid on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials.BMC Cardiovasc Disord. 2025 Feb 21;25(1):125. doi: 10.1186/s12872-025-04549-3. BMC Cardiovasc Disord. 2025. PMID: 39984850 Free PMC article.
-
Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.Hepatol Res. 2020 Apr;50(4):407-418. doi: 10.1111/hepr.13473. Epub 2020 Jan 13. Hepatol Res. 2020. PMID: 31840358 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources